Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

References

• Mattison R, Stock W. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008;3(3):144–151.
   Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012 30(14):1663–1669.
   PubMed Web of Science ®Google Scholar
• Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol. 2009;27(31):5189–5194.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535–1548.
   PubMed Web of Science ®Google Scholar
• Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev. 2004;30(1):37–51.
   PubMed Web of Science ®Google Scholar
• Eguiguren JM, Pui CH. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1992;20(1):58–60.
   Google Scholar
• Hann IM, Evans DI, Marsden HB, Jones PM, Palmer MK. Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood. J Clin Pathol. 1978;31(4):313–315.
   Web of Science ®Google Scholar
• Raney RB, McMillan CW. Simultaneous disparity of bone marrow specimens in acute leukemia. Am J Dis Child. 1969;117(5):548–552.
   Google Scholar
• Hann IM, Richards SM, Eden OB, Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia. 1998;12(8):1249–1255.
   Web of Science ®Google Scholar
• Ribeiro RC, Pui CH, Schell MJ. Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer. 1988;61(3):589–592.
   Web of Science ®Google Scholar
• Rogalsky RJ, Black GB, Reed MH. Orthopaedic manifestations of leukemia in children. J Bone Joint Surg Am. 1986;68(4):494–501.
   Google Scholar
• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043.
   PubMed Web of Science ®Google Scholar
• Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354(9189):1499–1503.
   PubMed Web of Science ®Google Scholar
• Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147–156.
   PubMed Web of Science ®Google Scholar
• Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975–2001. Bethesda, MD: National Cancer Institute; 2004. Available form: http://seer.cancer.gov/csr/1975_2001/. Accessed August 2, 2015.
   Google Scholar
• Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care. 2005;35(5):182–217.
   Google Scholar
• Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2005;130(2):166–173.
   Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer. 2006;47(6):748–756.
   PubMed Web of Science ®Google Scholar
• Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011; 8(7):417–424.
   Web of Science ®Google Scholar
• Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer. 2007; 110(11):2385–2393.
   Web of Science ®Google Scholar
• Collins SR, Schoen C, Kriss JL, Doty MM, Mahato B. Rite of passage? Why young adults become uninsured and how new policies can help. Issue Brief (Commonw Fund). 2006;20:1–14.
   PubMedGoogle Scholar
• Ibrahim A, Ali A, Mohammed MM. Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols. Adv Hematol. 2014;2014:697675.
   PubMedGoogle Scholar
• Fielding D, Duff A. Compliance with treatment protocols: interventions for children with chronic illness. Arch Dis Child. 1999; 80(2):196–200.
   Web of Science ®Google Scholar
• Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3):1094–1099.
   Web of Science ®Google Scholar
• Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):605–615.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr. 2005;217(6):310–320.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia. 2010;24(2):285–297.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2):265–284.
   PubMed Web of Science ®Google Scholar
• Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia. 2010;24(2):355–370.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia. 2010;24(2):320–334.
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Stock W, Johnson JL, Stone RM, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119(1):90–98.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28(7):1467–1471.
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998–1006.
   PubMed Web of Science ®Google Scholar
• Burke PW, Douer D. Acute lymphoblastic leukemia in adolescents and young adults. Acta Haematol. 2014;132(3–4):264–273.
   Web of Science ®Google Scholar
• Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St Jude experience. Cancer. 2004;101(7):1677–1684.
   PubMed Web of Science ®Google Scholar
• Advani AS, Sanford B, Luger S, et al. Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). 2013;122.
   Google Scholar
• Larsen EC, Salzer W, Nachman J, et al. Treatment toxicity in adolescents and young adult (AYA) patients compared with younger patients treated for high risk B-precursor acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group Study AALL0232 [ASH abstract 1510]. Blood. 2012;120(suppl 21):1510a.
   Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112(5):1646–1654.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28(2):97–113.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Putti MC, Colombini A, et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep. 2014;6(3):5554.
   Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896–904.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211–1218.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202–1210.
   PubMed Web of Science ®Google Scholar
• Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A. Adolescent and young adult (AYA) oncology in the United States: a specialty in its late adolescence. J Pediatr Hematol Oncol. 2015; 37(3):161–169.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–3889.
   PubMed Web of Science ®Google Scholar
• Stock W. Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21–29.
   PubMed Web of Science ®Google Scholar
• Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21(5):760–761.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Barr R. Cancer in young adults 20 to 39 years of age: overview. Semin Oncol. 2009;36(3):194–206.
   PubMed Web of Science ®Google Scholar
• Bleyer A. Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am. 2002;49(5):1027–1042.
   Web of Science ®Google Scholar
• Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011;29(30):4045–4053.
   Web of Science ®Google Scholar
• Stiller CA, Benjamin S, Cartwright RA, et al. Patterns of care and survival for adolescents and young adults with acute leukaemia – a population-based study. Br J Cancer. 1999;79(3–4):658–665.
   PubMed Web of Science ®Google Scholar
• Nachman J, Sather HN, Buckley JD, et al. Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993;71(Suppl 10):3377–3385.
   PubMed Web of Science ®Google Scholar
• Larson RA. The US trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004;83(Suppl 1):S127–S128.
   Google Scholar
• Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 2003;101(10):3809–3817.
   PubMed Web of Science ®Google Scholar
• Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005; 129(6):734–745.
   PubMed Web of Science ®Google Scholar
• Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25(7):813–819.
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774–780.
   PubMed Web of Science ®Google Scholar
• Testi A. Difference in outcome of adolescents (14–17 years) with acute lymphoblastic leukemia (ALL) enrolled in the Italian pediatric (AIEOP) and adult (GIMEMA) multicenter protocols. J Clinical Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(18S):9024.
   Google Scholar
• de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032–2035.
   PubMed Web of Science ®Google Scholar
• Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008; 93(8):1161–1168.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Thomas DA, O’Brien SM, et al. Augmented Berlin- Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014;120(23):3660–3668.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22(12):2142–2150.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–4023.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Annesley CE, Brown P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol. 2015;6(2):61–79.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6(5):228–241.
   PubMed Web of Science ®Google Scholar
• Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121(2):339–350.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
   PubMed Web of Science ®Google Scholar
• Seftel MD, Neuberg D, Zhang M-J, et al. Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. 2014;124:310.
   Google Scholar
• Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–2496; quiz 2586.
   PubMed Web of Science ®Google Scholar
• Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014;2014:421723.
   PubMedGoogle Scholar
• Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2014;4:CD010189.
   Web of Science ®Google Scholar
• Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant. 2015;50(9):1173–1179.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014;123(13):2017–2025.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J, Que W. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant. 2012;18(8):1164–1173.
   PubMed Web of Science ®Google Scholar